The addition of paclitaxel to doxorubicin and cisplatin and volume-directed radiation does not improve overall survival (OS) or long-term recurrence-free survival (RFS) in advanced endometrial cancer (EC): A randomized phase III NRG/Gynecologic Oncology Group (GOG) study.

•No significant difference in OS in women with advanced-stage endometrial cancer on cisplatin and doxorubicin +/− paclitaxel•Despite a slight protective effect on OS and long-term RFS, the addition of paclitaxel comes with increased neurotoxicity.•Second malignancies were reported in 36 patients, including 13 breast cancers occurring mostly in the arm with paclitaxel.